bridgebio oncology therapeutics inc - BBOT

BBOT

Close Chg Chg %
2.14 -0.16 -7.48%

Closed Market

1.98

-0.16 (7.48%)

Volume: 799.68K

Last Updated:

Nov 16, 2026, 4:00 PM EDT

Company Overview: bridgebio oncology therapeutics inc - BBOT

BBOT Key Data

Open

$2.13

Day Range

1.97 - 2.23

52 Week Range

1.99 - 14.87

Market Cap

$188.59M

Shares Outstanding

80.25M

Public Float

45.27M

Beta

0.83

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1,232.22

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

718.09K

 

BBOT Performance

1 Week
 
4.90%
 
1 Month
 
-24.11%
 
3 Months
 
-76.38%
 
1 Year
 
-83.69%
 
5 Years
 
N/A
 

BBOT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About bridgebio oncology therapeutics inc - BBOT

Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.

BBOT At a Glance

Bridgebio Oncology Therapeutics, Inc.
256 East Grand Avenue
South San Francisco, California 94080
Phone 1-650-405-4770 Revenue 0.00
Industry Biotechnology Net Income -134,044,000.00
Sector Health Technology Employees 92
Fiscal Year-end 12 / 2026
View SEC Filings

BBOT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 2.436
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.226
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.084

BBOT Efficiency

Revenue/Employee N/A
Income Per Employee -1,457,000.00
Receivables Turnover N/A
Total Asset Turnover N/A

BBOT Liquidity

Current Ratio 12.34
Quick Ratio 12.34
Cash Ratio 12.142

BBOT Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -41.661
Return on Equity -44.695
Return on Total Capital -32.389
Return on Invested Capital -44.529

BBOT Capital Structure

Total Debt to Total Equity 0.673
Total Debt to Total Capital 0.668
Total Debt to Total Assets 0.616
Long-Term Debt to Equity 0.546
Long-Term Debt to Total Capital 0.542
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bridgebio Oncology Therapeutics Inc - BBOT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - - 610.00K
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - - 610.00K
-
Depreciation
- - - 610.00K
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -
-
Gross Income
- - - (610.00K)
-
Gross Income Growth
- - - -
-
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
3.52K 41.69K 584.39K 145.21M
Research & Development
- - - 121.20M
-
Other SG&A
3.52K 41.69K 584.39K 24.01M
SGA Growth
-91.88% +1,084.43% +1,301.68% +24,748.00%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 725.00K
-
EBIT after Unusual Expense
(3.52K) (41.69K) (584.39K) (146.54M)
Non Operating Income/Expense
- - 8.18M 12.50M
-
Non-Operating Interest Income
- - 8.46M 11.34M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(3.52K) (41.69K) 7.60M (134.04M)
Pretax Income Growth
+91.88% -1,084.43% +18,327.75% -1,863.85%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(3.52K) (41.69K) 7.60M (134.04M)
Minority Interest Expense
- - - -
-
Net Income
(3.52K) (41.69K) 7.60M (134.04M)
Net Income Growth
+91.88% -1,084.43% +18,327.75% -1,863.85%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(3.52K) (41.69K) 7.60M (134.04M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(3.52K) (41.69K) 7.60M (134.04M)
EPS (Basic)
-0.0002 -0.002 0.3233 -4.3039
EPS (Basic) Growth
+90.48% -900.00% +16,265.00% -1,431.24%
Basic Shares Outstanding
20.48M 20.48M 23.51M 31.14M
EPS (Diluted)
-0.0002 -0.002 0.3233 -4.3039
EPS (Diluted) Growth
+90.48% -900.00% +16,265.00% -1,431.24%
Diluted Shares Outstanding
20.48M 20.48M 23.51M 31.14M
EBITDA
(3.52K) (41.69K) (584.39K) (145.21M)
EBITDA Growth
+91.88% -1,084.37% -1,301.75% -24,747.96%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 17.556
Number of Ratings 10 Current Quarters Estimate -0.449
FY Report Date 12 / 2026 Current Year's Estimate -2.324
Last Quarter’s Earnings -0.43 Median PE on CY Estimate N/A
Year Ago Earnings -4.30 Next Fiscal Year Estimate -1.828
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 5 10 10
Mean Estimate -0.45 -0.49 -2.32 -1.83
High Estimates -0.27 -0.44 -1.86 -1.36
Low Estimate -0.60 -0.57 -4.16 -2.33
Coefficient of Variance -19.15 -11.14 -28.37 -14.57

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 9
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Bridgebio Oncology Therapeutics Inc - BBOT

Date Name Shares Transaction Value
Oct 6, 2026 Yong Ben Chief Med & Dev Officer 43,529 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.94 per share 171,504.26
Oct 6, 2026 Marc Cobo Principal Accounting Officer 14,015 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.94 per share 55,219.10
Oct 6, 2026 Pedro J. Beltran President and CEO; Director 43,529 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.94 per share 171,504.26
Oct 6, 2026 Idan Elmelech COO & Principal Financial Ofcr 14,152 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.94 per share 55,758.88
Sep 15, 2026 Marc Cobo Principal Accounting Officer 14,141 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.52 per share 78,058.32
Sep 15, 2026 Marc Cobo Principal Accounting Officer 43,700 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Bridgebio Oncology Therapeutics Inc in the News